Pulmonx (LUNG) Liabilities and Shareholders Equity (2019 - 2025)

Pulmonx (LUNG) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $129.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 20.61% year-over-year to $129.3 million; the TTM figure through Dec 2025 stood at $565.5 million (down 15.28% YoY), while the FY2025 annual figure was $129.3 million, down 20.61% from the prior year.
• Liabilities and Shareholders Equity declined to $129.3 million in Q4 2025 per LUNG's latest filing, from $138.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $255.3 million in Q1 2021 and bottomed at $129.3 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $190.4 million across 5 years, with a median of $189.1 million in 2023.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 246.44% — and 2025, when it slipped 20.61%.
• Pulmonx's Liabilities and Shareholders Equity stood at $235.2 million in 2021, then declined by 17.65% to $193.7 million in 2022, then decreased by 8.21% to $177.8 million in 2023, then dropped by 8.4% to $162.8 million in 2024, then retreated by 20.61% to $129.3 million in 2025.
• Business Quant data shows LUNG's Liabilities and Shareholders Equity at $129.3 million in Q4 2025, $138.3 million in Q3 2025, and $147.2 million in Q2 2025.